Skip to main content
. 2012 Feb 22;32(8):2683–2695. doi: 10.1523/JNEUROSCI.4125-11.2011

Figure 11.

Figure 11.

Inhibition of RGS4 enhances the A1R-mediated anti-seizure effect in WT, but not in Nrb−/− mice. A, The RGS4 inhibitor CCG-4986 attenuates kainate (KA)-induced seizure in WT mice. Seizure severity was scored over time postinjection with kainate (25 mg/kg) in combination with one the following: DMSO vehicle (n = 11); CCG-4986 (20 mg/kg) (n = 12); DPCPX (0.5 mg/kg) (n = 8); CCG-4986 and DPCPX (n = 10). ***p < 0.001, kainate plus CCG4986 versus kainate alone. ##p < 0.01; ###p < 0.001, kainate alone versus kainate plus DPCPX. B, Coinjection of CCG-4986 reduces the percentage of WT mice exhibiting generalized seizure within 120 min post-kainate administration. WT mice treated with kainate alone or in combination with CCG-4986 or DPCPX, or both were compared. C, Coinjection of CCG-4986 reduces kainate-induced lethality in WT mice. Data are expressed as a percentage of death in WT mice treated with kainate alone or in combination with CCG-4986 or DPCPX, or both. D, The effect of RGS4 inhibition on kainate-induced seizure is negligible in Nrb−/− mice. Seizure severity was scored over time postinjection with kainate (25 mg/kg) in combination with DMSO vehicle (n = 8) or CCG-4986 (20 mg/kg) (n = 8). Error bars indicate mean ± SEM.